MarketPulse
F

$FATE

2 articles found
2 positive
0 negative
0 neutral
BenzingaBenzinga··Prnewswire

Cell Therapies Graduate to Mass Production as Market Eyes $8.2B Prize

Cell therapy companies achieve major manufacturing and clinical milestones, positioning sector for explosive growth as global market targets $8.2 billion by 2026.
MESOFATEFBLGLGVNbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

iPSC-Derived NK Cell Therapies Accelerate With 12+ Companies Advancing Pipeline

12+ companies advance iPSC-derived NK cell therapies for cancer treatment. Century Therapeutics and Fate Therapeutics report promising clinical progress in this expanding immunotherapy field.
IPSCFATEHLOSFclinical trialscancer treatment